Table 2.
Antioxidant activities of compounds (6a-f) in DPPH and ABTS assay.
|
Sample |
% inhibition ±SD* μg/ml |
IC50 ± SD μg/ml (μM) |
||||
|---|---|---|---|---|---|---|
| 5 | 10 | 25 | 50 | 100 | ||
| DPPH | ||||||
| 6d | 13.8 ± 0.2 | 26.0 ± 0.9 | 42.1 ± 0.6 | 46.2 ± 0.3 | 68.7 ± 0.1 | 58.8 ± 1.7 (35.2 ± 1.0)a |
| 6b | – | 18.9 ± 0.3 | 40.6 ± 0.9 | 58.5 ± 0.6 | 84.1 ± 0.2 | 32.4 ± 1.1(18.3 ± 0.6)b |
| 6a | 27.04 ± 0.2 | 40.2 ± 0.4 | 47.2 ± 1.0 | 53.2 ± 0.9 | 63.3 ± 0.8 | 32.6 ± 2.9(18.3 ± 1.6)b |
| 6e | 17.1 ± 0.6 | 33.8 ± 0.5 | 54.5 ± 0.4 | 60.7 ± 0.8 | 67.9 ± 0.6 | 18.5 ± 1.6(10.6 ± 0.9)d |
| 6f | 10.6 ± 0.9 | 20.7 ± 0.8 | 39.5 ± 0.5 | 48.9 ± 0.4 | 66.9 ± 0.3 | 56.2 ± 2.1 (30.8 ± 1.2)a |
| 6c | – | 24.6 ± 1.8 | 31.7 ± 0.3 | 52.2 ± 0.2 | 71.4 ± 0.7 | 43.1 ± 1.8 (24.3 ± 1.0)c |
| Trolox® | 5.2 ± 0.3 (1.3 ± 0.1)** | |||||
| ABTS | ||||||
| 6d | 21.1 ± 1.0 | 33.7 ± 0.7 | 42.8 ± 0.3 | 61.6 ± 0.6 | 66.5 ± 0.6 | 31.7 ± 1.9 (18.9 ± 1.1)e |
| 6b | 11.8 ± 0.5 | 28.3 ± 0.4 | 43.4 ± 0.3 | 53.9 ± 0.8 | 72.9 ± 0.5 | 35.3 ± 1.6 (19.8 ± 0.9)e |
| 6a | 22.7 ± 0.2 | 48.7 ± 0.5 | 53.5 ± 0.3 | 71.1 ± 1.0 | 75.5 ± 0.5 | 17.8 ± 1.1 (10.0 ± 0.6)f |
| 6e | 14.9 ± 1.4 | 37.0 ± 0.2 | 50.3 ± 0.5 | 71.2 ± 0.2 | 74.3 ± 0.4 | 24.2 ± 1.0 (13.9 ± 0.6)f |
| 6f | 13.3 ± 0.6 | 29.7 ± 0.7 | 46.1 ± 0.1 | 54.1 ± 0.7 | 64.2 ± 0.4 | 39.2 ± 2.1 (21.5 ± 1.2)e |
| 6c | 14.8 ± 0.6 | 33.3 ± 0.8 | 42.7 ± 0.4 | 59.8 ± 0.3 | 65.7 ± 0.1 | 35.1 ± 2.0 (19.8 ± 1.1)e |
| Trolox® | 2.7 ± 0.2 (0.7 ± 0.1)** | |||||
* Data represents the means ± standard deviation (SD). ** Statistically significant IC50 values compared to Trolox® (p˂0.05). The mean % inhibitions with similar letters are not significantly different from each other based on post hoc Tukey HSD test at p˂0.01.